Table 6

Number and percentages of patients who underwent a total hip replacement in the safety population (n=398)

Patients who underwent THRPlacebo (209)ASU-E (189)Total (398)p (Fisher)
Between baseline and month 42 (n (%))39/209* (18.7)44/189* (23.3)83/398 (20.9)0.269
Baseline JSW<2.5 mm (n (%))27/77 (35.1)27/67 (40.3)54/144 (37.5)0.605
Baseline JSW≥2.5 mm (n (%))12/130 (9.2)17/121 (14.0)29/251 (11.6)0.244
Within 6 months after the end of the trial at patient level (n (%))35/209* (16.7)38/189* (20.1)73/398 (18.3)0.437
Baseline JSW<2.5 mm (n (%))23/77 (29.9)24/67 (35.8)47/144 (32.6)0.480
Baseline JSW≥2.5 mm (n (%))12/130 (9.2)14/121 (11.6)26/251 (10.4)0.679
  • *Three patients had no target hip radiographs at baseline (two in the placebo group and one in the ASU-E group).

  • ASU-E, avocado–soybean unsaponifiable—Expanscience; JSW, joint space width; THR, total hip replacement.